Renaissance Technologies
DRMA icon

Renaissance Technologies’s Dermata Therapeutics DRMA Stock Holding History

Renaissance Technologies’s Portfolio DRMA Stock Details DRMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-176
Closed -$34K – 3998
2023
Q1 		$34K Buy
+176
New +$103K ﹤0.01% 3740
2022
Q1 		– Sell
-16
Closed -$68K – 4139
2021
Q4 		$68K Buy
+16
New +$141K ﹤0.01% 3749

Other funds holding DRMA

Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
HWA
HCR Wealth Advisors Los Angeles, California $1.12B AUM 33.13% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Renaissance Technologies's DRMA Position: Q2 2023 in Review

Renaissance Technologies sold out of Dermata Therapeutics (DRMA) in Q2 2023, closing a stake of 176 shares — an estimated $34K sold.

Renaissance Technologies first reported a position in DRMA in Q4 2021 and held it in 2 quarters. The position peaked at $68K in Q4 2021. 8 funds tracked by Wall St. Rank hold DRMA as of Q2 2023.

  • Renaissance Technologies reported no remaining Dermata Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Renaissance Technologies sold 176 Dermata Therapeutics shares in Q2 2023, an estimated $34K.
  • Renaissance Technologies first reported a position in Dermata Therapeutics in Q4 2021 and held it in 2 quarters.
  • Renaissance Technologies's Dermata Therapeutics position peaked at $68K in Q4 2021.
  • 8 funds tracked by Wall St. Rank held Dermata Therapeutics as of Q2 2023.

Based on Renaissance Technologies's 13F filing for Q2 2023, filed 11 Aug 2023.